Feasibility and healthcare costs of superpotent topical corticosteroid therapy in bullous pemphigoid: a prospective, observational study in an academic center in France.
The objectives of this study were to determine whether TCS alone were actually used as first-line therapy and could be successfully continued during the first year of treatment in routine practice, and to estimate the related healthcare costs.
PMID: 32320476 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Clapé A, Muller C, Plée J, Viguier M, Vanhaecke C, Bernard P Tags: Br J Dermatol Source Type: research
More News: Academia | Corticosteroid Therapy | Dermatology | France Health | Healthcare Costs | Pemphigoid | Skin | Study | UK Health